NEW YORK, Sept. 24, 2024
NEW YORK, Sept. 24, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The Global Immunology Market size is estimated to grow by USD 65.8 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 9.45% during the forecast period. Growing organ transplantation is driving market growth, with a trend towards significant pipeline of immunology However, entry of biosimilars poses a challenge - Key market players include 3SBio Inc., AbbVie Inc., Amgen Inc., ANTARES PHARMA INC., Astellas Pharma Inc., Biogen Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Horizon Therapeutics Plc, ImmuNext Inc., Incyte Corp., Johnson and Johnson Services Inc., Merck KGaA, Mitsubishi Chemical Group Corp., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA.
Advertisement
AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View your snapshot now
Advertisement
Forecast period
2024-2028
Base Year
2023
Historic Data
2018 - 2022
Segment Covered
Type (Immunosuppressants and Immuno boosters), Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), and Geography (North America, Europe, Asia, and Rest of World (ROW))
Region Covered
North America, Europe, Asia, and Rest of World (ROW)
Key companies profiled
3SBio Inc., AbbVie Inc., Amgen Inc., ANTARES PHARMA INC., Astellas Pharma Inc., Biogen Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Horizon Therapeutics Plc, ImmuNext Inc., Incyte Corp., Johnson and Johnson Services Inc., Merck KGaA, Mitsubishi Chemical Group Corp., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA
Key Market Trends Fueling Growth
The global immunology market is set to experience significant growth due to the advancement of numerous promising immunological agents in various clinical trial stages. As of October 2021, approximately 51 molecules are under development, with 22 in Phase II, four in Phase III, 16 in Phase I, and the remaining in Phase I/II trials. Notable developments include risankizumab (SKYRIZI) from AbbVie Inc., which is undergoing approval processes for new indications such as psoriasis, psoriatic arthritis, and Crohn disease. Additionally, AbbVie's ABBV-157 is in Phase I trials for the treatment of psoriatic arthritis. These advancements will broaden treatment options and increase demand for therapeutic regimens, contributing to the market's expansion during the forecast period.
The Immunology Market is experiencing significant growth due to the rising prevalence of microbes, viruses, and cancer cells. Systemic medications like interleukin-6 and tumor necrosis factor-alpha inhibitors, DMARDs, janus kinase inhibitors, methotrexate, and corticosteroids are dominating the market for diseases such as multiple sclerosis and psoriasis. Pharmacists play a crucial role in drug schedules and usage reviews. Innovative therapies, including biotechnology and molecular biology, are revolutionizing the treatment landscape for various diseases. Targeted immunotherapies, such as Rituximab and Adalimumab, are leading the way for reimbursement systems and personalized immunotherapies in cancer and allergies. Precision medicine and treatment modalities are also gaining popularity. The market for rare disorders and joint function in chronic inflammatory conditions is expected to grow, with biomarkers playing a key role in diagnosis and treatment. Reimbursement policies and clinical studies at academic institutions continue to drive research and development in this sector.
Insights on how AI is driving innovation, efficiency, and market growth- Request Sample!
Market Challenges
Insights into how AI is reshaping industries and driving growth- Download a Sample Report
Segment Overview
This immunology market report extensively covers market segmentation by
1.1 Immunosuppressants- The Immunology Market refers to the industry dedicated to researching, developing, and manufacturing products and services related to the human immune system. This market includes pharmaceutical companies, biotechnology firms, and research institutions. Key players in this market focus on creating innovative treatments and therapies for various immune-related disorders, such as autoimmune diseases and cancer. Collaborations and partnerships between these entities drive advancements in immunology research and technology. The market's growth is driven by an aging population, increasing prevalence of immune-related disorders, and rising healthcare expenditures.
Download complimentary Sample Report to gain insights into AI's impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 - 2022)
Research Analysis
The Immunology market encompasses a broad spectrum of products and services related to the study of the immune response, immune system, and related disorders. This includes therapies for infectious diseases, autoimmune disorders such as rheumatoid arthritis and psoriatic arthritis, and immune-related disorders like Type 1 diabetes. Innovative therapies in this field include biosimilars, biologics, monoclonal antibodies, and immune checkpoint inhibitors. Hospital pharmacies play a crucial role in the administration of these biological medications. Diagnostic tools like ELISA assays, flow cytometry, and PCR-based diagnostics are essential for identifying and monitoring immune disorders. Dysregulation of the immune response can lead to various immune responses, including autoimmune diseases, allergies, and cancer. The biotechnology industry is at the forefront of developing new immunology therapies and diagnostic tools to address these challenges.
Market Research Overview
The Immunology Market encompasses a broad spectrum of products and services related to the study of the immune response, immune system, and various immune-related disorders. These include infections, autoimmune disorders such as rheumatoid arthritis and psoriatic arthritis, and chronic illnesses like Type 1 diabetes. Innovative therapies in this field include monoclonal antibodies, fusion proteins, immunosuppressants, and biosimilars. Biologics and biological medications are also key areas of focus, with ELISA assays, flow cytometry, and PCR-based diagnostics used for testing and analysis. Immunomodulators, tests and assays, and immune system components are also crucial components of the market. Personalized medicine, genetic composition, and environmental factors such as toxic chemicals and gut dysbiosis are driving research in this field. Immunotherapies, including cancer immunotherapy, cancer cells, and immunotherapies like interleukin-6 and tumor necrosis factor-alpha inhibitors, are transforming oncology. Pharmacists play a vital role in managing drug schedules, usage reviews, and clinical studies at hospital pharmacies, retail pharmacies, and online pharmacies. Drug development continues to advance with the use of systemic medications, disease pathways, and side effects, as well as targeted therapies like tyrosine kinase inhibitors, CTLA-4 inhibitors, and adoptive cell therapy. Cytokines and the tumor microenvironment are also under investigation, as are immunosuppressive substances and innovative therapies like CAR-T cell therapy. The market is vast and ever-evolving, with a focus on addressing the complexities of the immune system and its role in various diseases.
Table of Contents:
1 Executive Summary2 Market Landscape3 Market Sizing4 Historic Market Size5 Five Forces Analysis6 Market Segmentation
7 Customer Landscape8 Geographic Landscape9 Drivers, Challenges, and Trends10 Company Landscape11 Company Analysis12 Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: [email protected]: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-immunology-market-is-projected-to-grow-by-usd-65-8-billion-from-2024-2028--with-ai-reshaping-the-landscape-and-increasing-organ-transplants-driving-revenue---technavio-302256625.html
SOURCE Technavio
